Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide
Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin
receptor-positive (SSTR+), neuroendocrine tumours of GEP-NEN